Details of the Drug

General Information of Drug (ID: DMSJ3Z5)

Drug Name
REGN1979
Indication
Disease Entry ICD 11 Status REF
B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD ID
D0AU2T
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03888105) Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)